Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Pasteur, the vaccines division of Sanofi, has inaugurated a $101m vaccine R&D facility, known internally as 'Building 95,' at Connaught Campus in north Toronto, as part of its plans to retain over 300 research positions and bring many of the company's scientists under one umbrella.
Subscribe to our email newsletter
The Toronto facility manufactures 5-component acellular pertussis combination vaccines, polio (IPV) vaccine, diphtheria and tetanus vaccines and has the ability to store paediatric vaccines to ensure secure supply for Canadian immunization programs.
Under the Biopharmaceutical Investment Program, a part of the Next Generation of Jobs Fund, the Ontario province has contributed $13.9m to the construction of the facility.
Sanofi Pasteur president Mark Lievonen said the ability to research, develop and manufacture vaccines puts Canada among a handful of countries with the domestic capability to respond to vaccine-preventable public health threats.
"The capabilities of the Connaught Campus make Sanofi Pasteur a strategic Canadian asset for the protection of public health," Lievonen said.